Skip to content

Posts by Farouc A. Jaffer, MD, PhD

  • In this video, Farouc Jaffer, MD, PhD, discusses why the Chronic Total Occlusion (CTO) Percutaneous Coronary Intervention Program is important for improving the safety and efficacy of treatment for patients with CTO.

  • Mass General physicians presented on the podium, moderated sessions and showcased posters over 50 times at the American College of Cardiology 2018 Scientific Sessions. Some of them answered the question: “What was the most interesting topic presented at this year’s Scientific Session?"

  • At the ACC.18 Scientific Session and Expo, physicians and researchers from Mass General's Corrigan Minehan Heart Center will present their world-leading research and innovative approaches. Here are the eight can't miss sessions and presentations.

  • Although female sex and increasing age have been associated with worse outcomes after percutaneous coronary intervention (PCI), a recent study found only age to be associated with a higher rate of in-hospital complications and lower technical success after chronic total occlusion (CTO)-PCI

  • Many patients with complex CAD are high-risk and ineligible for surgical treatment. Alternative and advanced interventions at Mass General are proving to be effective.


Dr. Farouc Jaffer graduated from Stanford University in 1990 with a B.S. in Mathematical and Computational Sciences, and received in MD and PhD in Biophysics from the University of Pennsylvania of Medicine in 1996. He completed a residency in internal medicine at the Brigham and Women's Hospital, followed by a fellowship in cardiovascular medicine and interventional cardiology at Massachusetts General Hospital. In 2003, he joined the Cardiology Division as faculty. Dr. Jaffer is currently an Associate Professor of Medicine at Harvard Medical School and an Attending Interventional Cardiologist at Massachusetts General Hospital. He is Director of Coronary Intervention and Director of the Chronic Total Occlusion (CTO) PCI Program at at Massachusetts Gneral Hospital. The MGH is a leading center for treating the most complex coronary blockages, such as CTO. Many patients, previously without options, have successfully underwent CTO PCI, and have experienced marked reductions in angina (chest pain) and shortness of breath. Dr. Jaffer is also a Principal Investigator in the MGH Cardiovascular Research Center where his NIH-funded laboratory develops novel molecular imaging approaches to image high-risk plaques and blood clots, to better prevent heart attacks, strokes, and venous blood clots.

Cardiovascular Care at Mass General

At Mass General, our world-class physicians and nurses specialize in specific forms of both heart and vascular disease, and work closely together to offer leading treatments and preventive care for cardiovascular conditions.